… Our findings are consistent with completed phase III studies of first-line gefitinib versus
chemotherapy, which reported no significant difference in OS between arms irrespective of EGFR …

… This study investigated maintenance gemcitabine or erlotinib versus observation, following
… demonstrate that maintenance therapy with EGFR TKIs (gefitinib and erlotinib) produces a …

… This study showed that erlotinib significantly prolonged … of erlotinib single-agent therapy
in recurrent GBM [38]. In colorectal cancer, single-agent treatment with TKIs (erlotinib, gefitinib) …

… studies reporting outcomes of platinum-resistant ovarian/non-small cell lung cancer cell lines
and tumours treated with either erlotinib or gefitinib. … study suggests that erlotinib treatment …

… All patients in this study were included in the analysis … study will be needed to validate our
results. Currently, a phase III trial of gefitinib versus erlotinib for patients with previously treated …

… The response rates and disease control rates in the gefitinib- and erlotinib-treated groups
in this study were 76.9% versus 74.4% (p = 0.575) and 90.1% versus 86.8% (p = 0.305), …

… in patients treated with gefitinib or erlotinib varied substantially among trials. In a phase II study
… Our search yielded a total of 496 potentially relevant studies with gefitinib or erlotinib. The …

… The primary objective of this study was to determine the efficacy of gefitinib or erlotinib in
patients with recurrent meningioma treated on the two NABTC trials. Six-month progression-…

… A total of 769 patients with NSCLC were treated with either gefitinib or erlotinib between …
between erlotinib and gefitinib regardless of the PFS and OS in the current study. Further …

… randomized studies that investigated erlotinib or gefitinib in … phase II study of single-agent
erlotinib as first-line therapy in … studies on tumor samples of patients entered in the study to …